CAS NO: | 94-62-2 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
200mg | 电议 |
1 g | 电议 |
5 g | 电议 |
10 g | 电议 |
50 g | 电议 |
生物活性 | Piperine, a natural alkaloid isolated fromPiper nigrumL, inhibitsP-glycoproteinandCYP3A4activities with anIC50value of 61.94±0.054 μg/mL in HeLa cell. | ||||||||||||||||
IC50& Target | IC50: 61.94±0.054 μg/mL (P-glycoprotein, HeLa cell)[1] | ||||||||||||||||
体外研究 (In Vitro) | Piperine has shown to possessin vitrocytotoxic activity and in silico studies. The IC50value is found to be 61.94±0.054 μg/mL and in silico studies, it has more number of hydrogen bonds with minimum binding and docking energy and may be considered as inhibitor of EGFR tyrosine kinase[1]. Piperine has been found to have immunomodulatory, anti-oxidant, anti-asthmatic, anti-carcinogenic, anti-inflammatory, anti-ulcer, and anti-amoebic properties[2]. Piperine could enhance the bioavailabilities of other drugs including rosuvastatin, peurarin and docetaxel (DOX) via inhibition of CYP3A and P-glycoprotein activity[3]. | ||||||||||||||||
体内研究 (In Vivo) | At the dose of 3.5 mg/kg, the bioavailability of piperine is calculated to be 25.36%. Its AUC0→tis unproportionally increased with doses, indicating a potential non-linear pharmacokinetics profile of piperine. It is found that the AUC0→tand C0of docetaxel and t1/2of piperine are significantly increased after their combination use, suggesting potential enhanced bioavailability of not only docetaxel but also piperine, which may lead to the overall enhanced pharmacological effects[3]. The phosphorylation of I-κB, p65, p38, ERK, and JNK is inhibited by piperine in a dose-dependent manner, indicating that piperine may be a potential anti-inflammatory drug both in endometritis and in otherS. aureus-induced diseases[4]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 285.34 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C17H19NO3 | ||||||||||||||||
CAS 号 | 94-62-2 | ||||||||||||||||
中文名称 | 胡椒碱;胡椒酰胺 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 50 mg/mL(175.23 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|